Blog

The Michigan Structural Heart Consortium (MISHC) is committed to improving the quality of care and outcomes for patients undergoing transcatheter valve procedures in Michigan. This work is built on a foundation of collaboration, shared learning, and a commitment to improving safety and quality.

The MISHC TAVR and Mitral Workgroups provide strategic guidance and clinical expertise to support the implementation of TAVR and mitral procedure goals, respectively. The Workgroups play key roles in ensuring the registry achieves its objectives, including improving patient outcomes and facilitating high-quality publications that advance knowledge and promote best practices in TAVR and mitral valve interventions.

The Workgroups guide data collection priorities, quality improvement initiatives, and the Blue Cross Blue Shield Value Based Reimbursement Program.

They encourage collaboration and communication among registry participants, including surgeons, coordinators, quality leaders, and abstractors, and develop strategies to enhance engagement beyond meeting attendance.

Membership includes Physician Champions, clinical leaders, and other key stakeholders within the Consortium from various specialties, institutions, and regions, fostering a broad range of perspectives.

Mitral Workgroup

Key accomplishments of the Mitral Workgroup thus far include:

• Meeting on 2/25, 3/18, 5/13, 7/29, and 9/25
• Identifying targets for mitral goals
• Adding imaging physicians to Mitral Workgroup participation – Georgi Fram, MD from Henry Ford, Richard Bloomingdale, MD from Corewell East, and Mohammad Kenaan, MD from Corewell West.
• Implement goals into MISHC mitral reports for 2025 Q1 

Current and future work includes:

• Identifying publishing tracks and potential authors
• Reviewing MISHC Mitral Goals performance
• Identifying Best Practice Protocol opportunities
• Developing Mitral Workgroup breakout session agenda

TAVR Workgroup

Key accomplishments of the TAVR workgroup include:

• Meeting on 5/28, 6/2, and 8/12 (next meeting is planned for 9/30)
• Integrating Physician Director participation into exit interviews
• Submitting a conduction abnormality impact on the need for pacemaker after TAVR abstract to the PCR London Valves meeting
   

Current and future work includes:

• Creating a Structural Heart Team Best Practice Protocol with collaboration from the TAVR workgroup/ MISHC

Determining themes for upcoming abstract submissions

We are excited to see how these Workgroups shape improvements to quality of care and outcomes for Michigan structural heart patients in the coming months and years.